Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 84,000 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: therapy Clear all

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: aldesleukin, ipilimumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Long COVID, Post-Acute COVID-19 Syndrome
Interventions: Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications for symptoms management; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 20 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions: Cisplatin, IMRT 6 weeks, IMRT 5 weeks; Drug · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 207
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 168 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 14
States / cities: Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more

Conditions: Leukemia, Multiple Myeloma
Interventions: CIK cells, etoposide, bcnu, cyclophosphamide, gemcitabine, vinorelbine, melphalan; Drug
Lead sponsor: Sally Arai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Fall Risk, Healthy Elderly
Interventions: AMES; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 65 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 409
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more

Conditions: Stress Urinary Incontinence
Interventions: AMDC-USR (iltamiocel), Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 20
States / cities: Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more

Conditions: Autism Spectrum Disorder, Language Disorders
Interventions: Levoleucovorin Calcium, Placebo; Drug · Other
Lead sponsor: Southwest Autism Research & Resource Center; Other
Eligibility: 30 Months to 60 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Brooklyn, New York

Conditions: Cachexia
Interventions: GSK2881078, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Overland Park, Kansas • Baltimore, Maryland

Conditions: Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions: Exenatide; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Boston, Massachusetts

Conditions: Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Interventions: Emavusertib, Gemcitabine, Cisplatin, Durvalumab; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, CHS-0214; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 37
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 32 more

Conditions: Drug Abuse
Interventions: screening, assessment, referral, Brief intervention, booster sessions; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 1,285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Miami, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 4 more

Conditions: Narcolepsy
Interventions: JZP-258; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 28
States / cities: Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more

Conditions: Pancreatic Cancer
Interventions: nal-IRI, 5 fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 29
States / cities: Mobile, Alabama • Avondale, Arizona • Phoenix, Arizona + 24 more

Conditions: Depression, Opioid Use, Chronic Pain, Anxiety
Interventions: Electronic medical recorded clinical decision support [EMR CDS], Stepped opioid collaborative care model [CCM]; Behavioral
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Migraine
Interventions: AVPI Device; Device
Lead sponsor: Nocira, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Saint Charles, Missouri • Springfield, Missouri

Conditions: Drug Addiction
Interventions: Enhanced care, control; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: marimastat; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 25
States / cities: Scottsdale, Arizona • Chicago, Illinois • Urbana, Illinois + 22 more

Conditions: Leukocyte Adhesion Deficiency Syndrome
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: SARS-CoV-2 Infection
Interventions: Intramuscular injection, Intramuscular vaccine; Drug · Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years and older
Enrollment: 30,918 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 45
States / cities: Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 39 more

Conditions: Alcoholism
Interventions: Prazosin medication, Placebo medication; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Training the Brain with a Robotic Device for Balance Recovery

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments

An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Opioid Treatment and Recovery Through a Safe Pain Management Program

AVPI Migraine Study

Treating the Partners of Drug Using Pregnant Women: Stage II

Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy

Gene Therapy for Patients With Leukocyte Adherence Deficiency (Follow-Up of Phase 1 Trial)

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Study of the Medication Prazosin for Alcohol Dependence